Drift, evolution, and divergence in biologics and biosimilars manufacturing

BioDrugs

Volumn 28, Issue 4, 2014, Pages 363-372

  Ramanan, Sundar ^a   Grampp, Gustavo ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL PRODUCT; BIOSIMILAR AGENT;

DRUG MANUFACTURE; DRUG QUALITY; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; PRIORITY JOURNAL; QUALITY CONTROL PROCEDURES; REVIEW; DRUG INDUSTRY; HUMAN; PROCEDURES; STANDARDS; SUPPLY AND DISTRIBUTION;

BIOLOGICAL PRODUCTS; BIOSIMILAR PHARMACEUTICALS; DRUG INDUSTRY; HUMANS; PHARMACOVIGILANCE;

EID: 84904857984     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.1007/s40259-014-0088-z     Document Type: Review

References (37)

1. US Food and Drug Administration. What is a biological product? http://www.fda.gov/AboutFDA/Transparency/Basics/ucm194516.htm. Accessed 20 Sept 2013.
2. Genazzani AA, Biggio G, Caputi AP, Del Tacca M, Drago F, Fantozzi R, Canonico PL. Biosimilar drugs: concerns and opportunities. BioDrugs. 2007;21(6):351-6. (Pubitemid 350145444)
3. Wiggins JM, Skutnik J, Shimek-Cox J, Schwarzwalder N. The ideal pharmacopeia: a model for the future. Pharm Technol. 2008;32(11):122-5.
4. Crommelin DJ, Storm G, Verrijk R, de Leede L, Jiskoot W, Hennink WE. Shifting paradigms: biopharmaceuticals versus low molecular weight drugs. Int J Pharm. 2003;266(1-2):3-16. (Pubitemid 37249303)
5. Chirino AJ, Mire-Sluis A. Characterizing biological products and assessing comparability following manufacturing changes. Nat Biotechnol. 2004;22(11):1383-91. doi:10.1038/nbt1030. (Pubitemid 39482857)
6. Berkowitz SA, Engen JR, Mazzeo JR, Jones GB. Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars. Nat Rev Drug Discov. 2012;11(7):527-40. doi:10.1038/nrd3746.
7. Glodek M, Liebowitz S, McCarthy R, McNally G, Oksanen C, Schultz T, Sundararajan M, Vorkapich R, Vukovinsky K, Watts C, Millili G. Process robustness - a PQRI white paper. Pharm Eng. 2006;26(6):1-11.
8. European Medicines Agency. Concept paper on the revision of the guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues. 2011. http://www.ema.europa.eu/ docs/en-GB/document-library/Scientific-guideline/2011/02/WC500102285.pdf. Accessed 20 Sept 2013.
9. The Patient Protection and Affordable Care Act. 2010. http://www.gpo.gov/fdsys/pkg/BILLS-111hr3590enr/pdf/BILLS-111hr3590enr.pdf. Accessed 27 Jan 2014.
10. Sherman RE. Biosimilar biological products. Biosimilar guidance webinar. 2012. http://www.fda.gov/downloads/drugs/developmentapprovalprocess/ howdrugsaredevelopedandapproved/approvalapplications/ therapeuticbiologicapplications/biosimilars/ucm292463.pdf. Accessed 20 Sept 2013.
11. US Department of Health and Human Services. Guidance for industry quality systems approach to pharmaceutical CGMP regulations. 2006. http://www.fda.gov/ downloads/Drugs/.../Guidances/UCM070337.pdf. Accessed 20 Sept 2013.
12. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. Pharmaceutical quality system: Q10. ICH harmonized tripartite guideline. 2008. http://www.ich.org/fileadmin/ Public-Web-Site/ICH-Products/Guidelines/Quality/Q10/Step4/Q10-Guideline.pdf. Accessed 20 Sept 2013.
13. Szymczak MM, Friedman RL, Uppoor R, Yacobi A. Detection, measurement, and control in pharma manufacturing. Pharm Technol. 2011;70-76.
14. US Food and Drug Administration. Guidance for industry: changes to an approved application for specified biotechnology and specified synthetic biological products. 1997. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm124805.pdf. Accessed 20 Sept 2013.
15. US Food and Drug Administration. Guidance for industry: comparability protocols - chemistry, manufacturing, and controls information. 2003. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm070545.pdf. Accessed 20 Sept 2013.
16. European Medicines Agency. Comparability of biotechnological/biological products subject to changes in their manufacturing process. http://www.ema. europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500002805. pdf. Accessed 22 Oct 2013.
17. Fundamentals of US regulatory affairs, seventh edition. Regulatory Affairs Professionals Society. Maryland: Rockville; 2011.
18. Lee JF, Litten JB, Grampp G. Comparability and biosimilarity: considerations for the healthcare provider. Curr Med Res Opin. 2012;28(6):1053-8. doi:10.1185/03007995.2012.686902.
19. Schneider CK. Biosimilars in rheumatology: the wind of change. Ann Rheum Dis. 2013;72(3):315-8. doi:10.1136/annrheumdis-2012-202941.
20. European Medicines Agency. Aranesp: changes made after 1 September 2003. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Procedural-steps- taken-and-scientific-information-after-authorisation/human/000332/WC500026145. pdf. Accessed 20 Sept 2013.
21. Schiestl M, Stangler T, Torella C, Cepeljnik T, Toll H, Grau R. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol. 2011;29(4):310-2. doi:10.1038/nbt.1839.
22. European Medicines Agency. Aranesp: darbepoetin alfa. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/ 000332/human-med-000651.jsp&murl=menus/medicines/. Accessed 22 Oct 2013.
23. European Medicines Agency. Summary of opinion (post authorization): Erbitux. 2011. http://www.ema.europa.eu/docs/en-GB/document-library/Summary-of- opinion/human/000558/WC500117820.pdf. Accessed 20 Sept 2013.
24. Erbitux US prescribers information, Updated 2011. http://www.accessdata. fda.gov/drugsatfda-docs/label/2011/125084s153lbl.pdf. Accessed 16 Sept 2013.
25. Cohen MH, Chen H, Shord S, Fuchs C, He K, Zhao H, Sickafuse S, Keegan P, Pazdur R. Approval summary: cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer. Oncologist. 2013;18(4):460-6. doi:10.1634/theoncologist.2012-0458.
26. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, Michaud P, Papo T, Ugo V, Teyssandier I, Varet B, Mayeux P. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med. 2002;346(7):469-75. doi:10.1056/NEJMoa011931. (Pubitemid 34441737)
27. Locatelli F, Del Vecchio L, Pozzoni P. Pure red-cell aplasia "epidemic" - mystery completely revealed? Perit Dial Int. 2007;27(Suppl 2):S303-7. (Pubitemid 350047719)
28. US Food and Drug Administration. Guidance for industry: good pharmacovigilance practices and pharmacoepidemiologic assessment. 2005. http://www.fda.gov/downloads/regulatoryinformation/guidances/ucm126834.pdf. Accessed 20 Sept 2013.
29. Wieser C, Rosenkranz AR. Pure red cell aplasia after treatment of renal anaemia with epoetin theta. Clin Kidney J. 2013;6:539-42.
30. Kozlowski S, Woodcock J, Midthun K, Sherman RB. Developing the nation's biosimilars program. N Engl J Med. 2011;365(5):385-8. doi:10.1056/NEJMp1107285.
31. Casadevall N, Edwards IR, Felix T, Graze PR, Litten JB, Strober BE, Warnock DG. Pharmacovigilance and biosimilars: considerations, needs and challenges. Expert Opin Biol Ther. 2013;13(7):1039-47. doi:10.1517/14712598. 2013.783560.
32. Directive 2010/84/EU of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmaco-vigilance, directive 2001/83/EC on the Community code relating to medicinal products for human use. Off J Eur Union. 2010;348:74-99.
33. US Food and Drug Administration. Guidance for industry: scientific considerations in demonstrating biosimilarity to a reference product. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM291128.pdf. Accessed 22 Oct 2013.
34. Biologics Price Competition and Innovation Act of 2009; 2010.
35. Abood RR. Pharmacy practice and the law. 7th ed. Burlington, MA. 2012.
36. McCamish M, Woollett G. The state of the art in the development of biosimilars. Clin Pharmacol Ther. 2012;91(3):405-17. doi:10.1038/clpt.2011.343.
37. Weise M, Bielsky MC, De Smet K, Ehmann F, Ekman N, Giezen TJ, Gravanis I, Heim HK, Heinonen E, Ho K, Moreau A, Narayanan G, Kruse NA, Reichmann G, Thorpe R, van Aerts L, Vleminckx C, Wadhwa M, Schneider CK. Biosimilars: what clinicians should know. Blood. 2012;120(26):5111-7. doi:10.1182/blood-2012-04- 425744.